ライフサイエンスコーパス: osteoporotic

1 ne loss, while gain-of-function animals were osteoporotic.

2 < 0.001), suggesting that they were becoming osteoporotic.

3 ere we demonstrate that Abl-/- mice are also osteoporotic.

4 clinical data concerning the effects of anti-osteoporotic agents on bone properties.

5 y B-cell knockout (KO) mice were found to be osteoporotic and deficient in BM OPG, phenomena rescued

6 y secondary to an interaction of traditional osteoporotic and HIV-specific risk factors, and possibly

7 g of the physicochemical differences between osteoporotic and normal conditions will facilitate the d

8 nalysis on a gene expression data of normal, osteoporotic and osteomyelitis bone conditions.

9 e-targeting system prevented bone loss in an osteoporotic animal model.

10 patients with normal BMD at baseline became osteoporotic at 5 years.

11 995 g/cm(2), and 18 patients (45%) showed an osteoporotic BMD (T score less than -2.5) of at least tw

12 Most interestingly, we show that osteoporotic bone cells experience similar or higher max

13 s in vivo, and the mechanical environment of osteoporotic bone cells is not known.

14 Osteoporotic bone fracture rates are highest in countrie

15 er, the relation between protein and risk of osteoporotic bone fractures among individuals has not be

16 osteocytes and osteoblasts from healthy and osteoporotic bone in a rat model of osteoporosis.

17 maintains bone formation, thereby preventing osteoporotic bone loss induced by ovariectomy in adult m

18 OPG in OPG(-/-) mice effectively rescue the osteoporotic bone phenotype observed in OPG-deficient mi

19 difference between bone cells in healthy and osteoporotic bone.

20 Osteoporotic bones have reduced spongy bone mass, altere

21 tical bone in the distal metaphysis was made osteoporotic by dexamethasone, but was then replaced thr

22 ific conditional S1P(1) knockout mice showed osteoporotic changes due to increased osteoclast attachm

23 and pain-related disability associated with osteoporotic compression fractures in patients treated w

24 ive for the treatment of pain resulting from osteoporotic compression fractures is described.

25 as established to mimic human postmenopausal osteoporotic conditions under nutrient deficiency.

26 duct could provide insights regarding common osteoporotic conditions, such as postmenopausal and seni

27 disease) and 53 age- and gender-matched non-osteoporotic controls.

28 influence new bone formation in a 3 mm femur osteoporotic defect model in ovariectomized rats.

29 ased bone formation, and caused a subsequent osteoporotic deficit, including decreased trabecular bon

30 mation of hyperresorptive OCs and preventing osteoporotic deficits.

31 omen who were currently on prescription anti-osteoporotic drugs and any individuals deemed to be unsu

32 del may serve as a suitable tool to evaluate osteoporotic drugs and new biomaterials or fracture impl

33 these post-menopausal women not yet on anti-osteoporotic drugs.

34 f marrow cavities, liver avoidance, and anti-osteoporotic effects.

35 ysis, we showed that GPR40(-/-) mice exhibit osteoporotic features suggesting a positive role of GPR4

36 ing lithium chloride in Runx2-overexpressing osteoporotic female mice rescued the Wnt/beta-catenin si

37 ram for postmenopausal females, particularly osteoporotic females, who are at greater risk of tooth l

38 Osteoporotic fracture (11.9%) was also more common in cl

39 THR patients who had experienced a previous osteoporotic fracture (HR 0.48, 95% CI 0.23-0.99).

40 [HR], 1.43 [95% CI, 1.16 to 1.78]) and major osteoporotic fracture (HR, 1.21 [95% CI, 1.01 to 1.45])

41 the highest tertile had a lower risk of any osteoporotic fracture (HR: 0.65; 95% CI: 0.47, 0.88), ma

42 acture (HR: 0.65; 95% CI: 0.47, 0.88), major osteoporotic fracture (HR: 0.66; 95% CI: 0.45, 0.95), an

43 iated with a 30% decrease in the risk of any osteoporotic fracture (HR: 0.70; 95% CI: 0.50, 0.96).

44 me fracture (occurring after age 13 y) or an osteoporotic fracture (occurring after age 50 y).

45 The decreased risks seen for osteoporotic fracture and colorectal cancer were outweig

46 treatment, including reductions in risks of osteoporotic fracture and coronary heart disease, and th

47 ted whether MI constitutes a risk factor for osteoporotic fracture and examined secular trends in thi

48 erved for higher intake of flavonols for any osteoporotic fracture and major osteoporotic fracture, a

49 rea under the curve (AUC) for incident major osteoporotic fracture discrimination (AUC: FRAX with BMD

50 ars or older, who have been hospitalized for osteoporotic fracture from 2003 until 2005.

51 to LMWH) in 0.11% (95% CI, 0.02%-0.32%), and osteoporotic fracture in 0.04% (95% CI, < 0.01%-0.20%) o

52 ncreasing evidence suggests that the risk of osteoporotic fracture in adulthood could be determined p

53 risk factors for low bone mineral density or osteoporotic fracture in men or comparing 2 different me

54 eveloping strategies to reduce the burden of osteoporotic fracture in the population.

55 ead to longlasting reductions in the risk of osteoporotic fracture in their offspring.

56 ce in transfer are significant predictors of osteoporotic fracture in white female nursing home resid

57 B-12 and folic acid supplementation reduces osteoporotic fracture incidence in hyperhomocysteinemic

58 folic acid supplementation had no effect on osteoporotic fracture incidence in this elderly populati

59 Osteoporotic fracture is a significant source of morbidi

60 Documented osteoporotic fracture occurring during follow-up as a fu

61 roup analyses suggest a beneficial effect on osteoporotic fracture prevention in compliant persons ag

62 Incidence of osteoporotic fracture requiring hospitalization was dete

63 or modulator) have each been shown to reduce osteoporotic fracture risk among men receiving androgen-

64 drugs available for these diseases, reducing osteoporotic fracture risk by 50-60% in persons with low

65 concentrations may be associated with lower osteoporotic fracture risk in older adults, particularly

66 sorders and psychotropic medication use with osteoporotic fracture risk in routine clinical practice.

67 The observed 10-year major osteoporotic fracture risk of 6.3% (95% CI, 3.4-9.2%) wa

68 ersons aged >80 y, in per-protocol analyses, osteoporotic fracture risk was lower in the intervention

69 Osteoporotic fracture risk was not significantly differe

70 Research shows that optimal screening for osteoporotic fracture risk will require risk factor info

71 hly heritable trait and a key determinant of osteoporotic fracture risk, but the genes responsible ar

72 as a clinical aid to assess an individual's osteoporotic fracture risk, with or without bone mineral

73 bone remodeling associated with an increased osteoporotic fracture risk.

74 proves bone mineral density, a surrogate for osteoporotic fracture risk.

75 e important dietary components that modulate osteoporotic fracture risk.

76 etic component and an important predictor of osteoporotic fracture risk.

77 n in early life, midlife, and late life with osteoporotic fracture risk.

78 n, vitamin D and calcium deficiency increase osteoporotic fracture risk.

79 men with DM; HRs for 1-unit increase in FRAX osteoporotic fracture score, 1.04; 95% CI, 1.02-1.05, fo

80 Major osteoporotic fracture scores showed significant fracture

81 Risk of hip or major osteoporotic fracture through 2009 or 12 years following

82 , 0.6-1.4), whereas the relative risk for an osteoporotic fracture was 1.4 (95% CI, 0.7-2.7).

83 Tool score, or FRAX), 10-year risk for major osteoporotic fracture was greater than 20% (FRAX), quant

84 A family history of osteoporotic fracture was strongly associated with low B

85 Following an osteoporotic fracture, a multidisciplinary rehabilitatio

86 did not have a significantly reduced risk of osteoporotic fracture, although there was a trend toward

87 vity, prolonged corticosteroid use, previous osteoporotic fracture, and androgen deprivation therapy.

88 omen; 212 (17.8%) were identified as a major osteoporotic fracture, and of these, 129 (10.9%) were a

89 0-60% in persons with low bone mass or prior osteoporotic fracture, and SREs by one-third in cancer p

90 nols for any osteoporotic fracture and major osteoporotic fracture, as well as flavones for hip fract

91 ach of the studies and at each major site of osteoporotic fracture, including the hip and wrist.

92 Outcome measures were time to osteoporotic fracture, overall and by anatomic site, and

93 In elderly men, who are at greatest risk for osteoporotic fracture, the influence of hypogonadism on

94 fully improve the prediction of hip or major osteoporotic fracture.

95 a means to improve bone strength and reduce osteoporotic fracture.

96 oteins increase the risk of osteoporosis and osteoporotic fracture.

97 Vertebral fractures are the most common osteoporotic fracture.

98 d bone mineral density and increased risk of osteoporotic fracture.

99 to maximize efficacy in patients at risk for osteoporotic fracture.

100 ross-linking, thereby increasing the risk of osteoporotic fracture.

101 ed to low bone density and increased risk of osteoporotic fracture.

102 , bone mineral density, and the incidence of osteoporotic fracture.

103 functioning and thus may reduce the risk for osteoporotic fracture.

104 ement bone densitometry in assessing risk of osteoporotic fracture.

105 at is significantly related to bone mass and osteoporotic fracture.

106 ccurately identify those at greatest risk of osteoporotic fracture.

107 The primary endpoint was time to first osteoporotic fracture.

108 lomipramine (CLP), have an increased risk of osteoporotic fracture.

109 rs) after cohort entry for an incident major osteoporotic fracture.

110 ral density (BMD) predicts the likelihood of osteoporotic fracture.

111 up, 21 (4.6%) recipients experienced a major osteoporotic fracture.

112 ure and 113 participants experienced a major osteoporotic fracture.

113 Furthermore, paraffin sections of human osteoporotic fractured bone exhibited increased RANKL im

114 This study [B-vitamins for the PRevention Of Osteoporotic Fractures (B-PROOF)] aimed to determine whe

115 Incident nontraumatic major osteoporotic fractures (MOFs) and hip fractures.

116 femoral neck) and an increased risk of both osteoporotic fractures (odds ratio [OR] 1.3, 95% CI 1.09

117 e of both risk alleles increased the risk of osteoporotic fractures (OR 1.3, 1.08-1.63, p=0.006) and

118 ificantly associated with the development of osteoporotic fractures (relative risk [RR] 2.5, 95% conf

119 ociated with a small increase in the risk of osteoporotic fractures (RR 1.3, 95% CI 1.0, 1.8); howeve

120 women ages > or = 65 years from the Study of Osteoporotic Fractures (SOF) and white men and women age

121 y community-dwelling women from the Study of Osteoporotic Fractures (SOF) cohort (mean age 83 years)

122 The Study of Osteoporotic Fractures (SOF) is a prospective, observati

123 Pittsburgh Clinical Center for the Study of Osteoporotic Fractures (SOF), a prospective cohort study

124 the Pittsburgh Field Center of the Study of Osteoporotic Fractures (SOF), a prospective study of a c

125 with adjudicated fracture outcomes (Study of Osteoporotic Fractures [December 1998-July 2008]; Osteop

126 mitigating bone loss and in reducing risk of osteoporotic fractures among older adults.

127 amined magnesium intake as a risk factor for osteoporotic fractures and altered bone mineral density

128 Benefits of HRT include prevention of osteoporotic fractures and colorectal cancer, while prev

129 Osteoporotic fractures and osteoporosis were found in 37

130 e-related disorder leading to an increase in osteoporotic fractures and resulting in significant suff

131 Osteoporotic fractures are a leading cause of disability

132 Although methods to identify risk for osteoporotic fractures are available and medications to

133 Osteoporotic fractures are common among elderly men.

134 of the use of cimetidine on osteoporosis and osteoporotic fractures are indicated.

135 at BPs dispensed for secondary prevention of osteoporotic fractures are not associated with increased

136 an women, age >/=65 years, from the Study of Osteoporotic Fractures cohort was performed.

137 The Study of Osteoporotic Fractures followed up 8022 women for 9.1 ye

138 udies, the Beijing OA Study and the Study of Osteoporotic Fractures from the US.

139 The aims are to establish the prevalence of osteoporotic fractures in ISM and to investigate the ass

140 ation-based age-specific fracture rates; the Osteoporotic Fractures in Men (MrOS) study and published

141 n Older Men Study (an ancillary study to the Osteoporotic Fractures in Men (MrOS) Study conducted in

142 The Osteoporotic Fractures in Men (MrOS) study is the first

143 porotic Fractures [December 1998-July 2008]; Osteoporotic Fractures in Men Study [March 2000-March 20

144 The Osteoporotic Fractures in Men Study followed up 5995 men

145 d DHEA-S in the prospective population-based Osteoporotic Fractures in Men study in Sweden (2,416 men

146 In a cohort of 1,104 elderly men from the Osteoporotic Fractures in Men Study, 25(OH)D serum level

147 sical performance with incident falls in the Osteoporotic Fractures in Men Study, a large prospective

148 study of 2,865 participants derived from the Osteoporotic Fractures in Men Study, a prospective multi

149 >/=65 years of age who were enrolled in the Osteoporotic Fractures in Men Study.

150 Participants were recruited from the Osteoporotic Fractures in Men Study.

151 to osteoporosis and to estimate the risk of osteoporotic fractures in relation to body weight, lean

152 The number of osteoporotic fractures in the groups was similar.

153 Participants in the Study of Osteoporotic Fractures in whom pelvic radiographs had be

154 past decades, the association between MI and osteoporotic fractures increased steadily.

155 assessed at the baseline Caregiver-Study of Osteoporotic Fractures interview, conducted in 1999-2001

156 in patients with ISM shows that the risk of osteoporotic fractures is high, especially in men.

157 Protection against osteoporotic fractures is supported by a meta-analysis o

158 ssary component of bone, but its relation to osteoporotic fractures is unclear.

159 Falls are the chief mechanism by which osteoporotic fractures occur.

160 A total of 223 osteoporotic fractures occurred among 180 women.

161 Osteoporotic fractures occurred in 61 persons (4.2%) in

162 Only osteoporotic fractures of the hip, vertebrae, and wrist

163 Osteoporotic fractures present a significant social and

164 Although osteoporotic fractures present an enormous health burden

165 Osteoporotic fractures represent an enormous public heal

166 01 elderly women from the Caregiver-Study of Osteoporotic Fractures sample.

167 treatment to limit the enormous increase in osteoporotic fractures that has been predicted as the ag

168 five families with X-linked osteoporosis and osteoporotic fractures that we report here.

169 We used data from the prospective Study of Osteoporotic Fractures to estimate risk of fracture from

170 The ability to identify patients with osteoporotic fractures was evaluated by using receiver o

171 ort of 5,552 elderly women from the Study of Osteoporotic Fractures was followed up prospectively for

172 Osteoporotic fractures were determined from medical reco

173 Over 10 y of follow-up, osteoporotic fractures were identified in 288 (24.2%) wo

174 We studied 5,839 women from the Study of Osteoporotic Fractures who had had serial pelvic radiogr

175 Reducing osteoporotic fractures will require more effective appro

176 ith AFFs to those from patients with typical osteoporotic fractures with and without bisphosphonate t

177 association between the replicated SNPs and osteoporotic fractures with data from two studies.

178 > or =74 years participating in the Study of Osteoporotic Fractures year 10 follow-up (n = 906) in 19

179 52 patients were reviewed (121 patients with osteoporotic fractures, 30 with malignant disease, and o

180 ls, among 6,653 participants in the Study of Osteoporotic Fractures, a community-based, prospective c

181 linical centers and enrolled in the Study of Osteoporotic Fractures, a longitudinal cohort study.

182 The Study of Osteoporotic Fractures, a prospective cohort study of wh

183 ncer risk factors, clinical risk factors for osteoporotic fractures, and bone mineral density surveil

184 D) is highly heritable, a major predictor of osteoporotic fractures, and has been previously associat

185 elderly white women enrolled in the Study of Osteoporotic Fractures, and initial breast cancer status

186 ing health outcomes, including prevention of osteoporotic fractures, is essential for promoting the w

187 study population was drawn from the Study of Osteoporotic Fractures, Pittsburgh, Pennsylvania, during

188 Given the economic and social costs of osteoporotic fractures, strategies to identify and manag

189 aging needs to be used to diagnose prevalent osteoporotic fractures, such as spine fractures on chest

190 Despite African Americans' reduced risk of osteoporotic fractures, such fractures remain an importa

191 that many agents are effective in preventing osteoporotic fractures, the data are insufficient to det

192 om bisphosphonate-treated women with typical osteoporotic fractures.

193 frican-American participants in the Study of Osteoporotic Fractures.

194 associated with a 4-fold increased risk for osteoporotic fractures.

195 hniques should be used to diagnose prevalent osteoporotic fractures.

196 1 older US women from the Caregiver-Study of Osteoporotic Fractures.

197 t been systematically studied in relation to osteoporotic fractures.

198 and April 2004 in a substudy of the Study of Osteoporotic Fractures.

199 eric femur that are infrequently affected by osteoporotic fractures.

200 d the exercise type most effective to reduce osteoporotic fractures.

201 tive was to examine FA intake in relation to osteoporotic fractures.

202 wered hip BMD but did not change the risk of osteoporotic fractures.

203 tate cancer is associated with bone loss and osteoporotic fractures.

204 gnificant gene BDNF was also associated with osteoporotic fractures.

205 ars of age who were enrolled in the Study of Osteoporotic Fractures.

206 independent risk factor for osteoporosis and osteoporotic fractures.

207 Patients with RA are at increased risk of osteoporotic fractures.

208 or =65 years of age enrolled in the Study of Osteoporotic Fractures.

209 of the hip in elderly women in the Study of Osteoporotic Fractures.

210 at the baseline examination of the Study of Osteoporotic Fractures.

211 at the baseline examination of the Study of Osteoporotic Fractures.

212 rly women are associated with a reduction in osteoporotic fractures.

213 uman beings and thereby decrease the risk of osteoporotic fractures.

214 hosphonates are a common treatment to reduce osteoporotic fractures.

215 es may be consistent with a reduction in all osteoporotic fractures.

216 at 26 million American women are at risk for osteoporotic fractures.

217 od most often used to determine the risk for osteoporotic fractures.

218 of sex and racial differences in the risk of osteoporotic fractures.

219 of age or older and enrolled in the Study of Osteoporotic Fractures.

220 c kidney disease, chronic liver disease, and osteoporotic fractures.

221 Ps in the setting of secondary prevention of osteoporotic fractures.

222 ysteine concentrations are a risk factor for osteoporotic fractures.

223 but also to contribute to the development of osteoporotic fractures.

224 , and low risk of fractures [HR (95% CI) for osteoporotic fractures: 0.90 (0.83, 0.96); for hip fract

225 and high risk of fractures [HR (95% CI) for osteoporotic fractures: 1.08 (1.00, 1.06); for hip fract

226 1% of patients, respectively, and 60% of the osteoporotic group had > or = 1 abnormal metabolic bone

227 , the OR (95% CI) for the low, moderate, and osteoporotic groups were 2.66 (1.12 to 6.29), 2.31 (0.89

228 and 230% for those in the low, moderate, and osteoporotic groups, respectively.

229 tioxidant intake was associated with risk of osteoporotic hip fracture and whether this association w

230 t intake was associated with reduced risk of osteoporotic hip fracture in these elderly subjects, and

231 The role of antioxidant intake in osteoporotic hip fracture risk is uncertain and may be m

232 5 T in 23 postmenopausal study patients with osteoporotic hip fractures, 27 age-matched healthy postm

233 postmenopausal women with and those without osteoporotic hip fractures.

234 fractures resulting from high trauma are not osteoporotic; however, this assumption has not been stud

235 y absorptiometry [DXA]) were normal, low, or osteoporotic in 24%, 55%, and 21% of patients, respectiv

236 ferentiates metastatic spinal fractures from osteoporotic lesions.

237 hese results support our hypothesis that the osteoporotic-like phenotype observed after Pb exposure i

238 low strain rates reflects susceptibility for osteoporotic low-energy fragility fractures.

239 ime fractures in 154 patients, including 140 osteoporotic (low-energy trauma) fractures, of which 62%

240 low -1.00 to -2.00; moderate -2.01 to -2.49; osteoporotic <-2.5).

241 In men, the prevalence of these osteoporotic manifestations (46% <50 years; 73% >/=50 ye

242 levels are associated with a higher risk of osteoporotic manifestations.

243 urinary MH were independently related to the osteoporotic manifestations.

244 lorothiazide treatment in hypercalciuric and osteoporotic men was associated with a rapid rebound inc

245 LD were applied to ovariectomy (OVX)-induced osteoporotic mice and the experiments were evaluated.

246 to regenerate critical-sized bone defects in osteoporotic mice by targeting Gsk-3beta to activate the

247 cells in culture and increased bone mass in osteoporotic mice in vivo.

248 neral density and bone micro-architecture in osteoporotic mice.

249 In the ovariectomy (OVX)-induced osteoporotic mouse model, serum and bone marrow levels o

250 first-time, single-level vertebroplasty for osteoporotic or traumatic compression fractures were exa

251 l incidence of vascular calcification in the osteoporotic patient population.

252 For 3 years, 30 osteoporotic patients after LTX (28+/-6 months) were tre

253 s able to restore skeletal integrity in most osteoporotic patients and the long-term use of osteoporo

254 Bone marrow stem cells from osteoporotic patients are more likely to differentiate i

255 success of sclerostin antibodies in treating osteoporotic patients despite increased osteocyte-expres

256 Fitting implants in osteoporotic patients has traditionally been controversi

257 examine the risk of developing gallstone in osteoporotic patients in Taiwan.

258 We hypothesized osteoporotic patients might have higher risk in developi

259 reduced fracture risk in both osteopenic and osteoporotic patients, whereas bisphosphonates were asso

260 and subsequent management of postmenopausal osteoporotic patients.

261 strategy to promote bone tissue formation in osteoporotic patients.

262 itis groups, but when non-smoking osteopenic/osteoporotic periodontitis patients were evaluated, E2-d

263 Prevention of falls among frail, osteoporotic persons would likely reduce the frequency o

264 The osteoporotic phenotype is not due to accelerated bone tu

265 Consistently, H2S-deficient mice display an osteoporotic phenotype that can be rescued by small mole

266 h osteoclast-specific Fbw7 ablation revealed osteoporotic phenotypes reminiscent of HCS, due to eleva

267 associated with increased bone resorption in osteoporotic post-menopausal women.

268 (99m)Tc-MDP plasma clearance (K(bone)) in 12 osteoporotic postmenopausal women (mean age, 67.3 y) bef

269 gested before recommendations for use in non-osteoporotic postmenopausal women with primary breast ca

270 of breast cancer in both high- and low-risk (osteoporotic) postmenopausal women.

271 that several medications for bone density in osteoporotic range and/or preexisting hip or vertebral f

272 ge animal model, local delivery of NELL-1 to osteoporotic sheep spine leads to significant increase i

273 Osteoporotic subjects had worse ACH (odds ratio [OR] = 1

274 ent for age attenuated the association, with osteoporotic subjects having a 1.9-fold increase of bein

275 h MR imaging, and postmenopausal healthy and osteoporotic subjects only with CT and DXA.

276 y, these results were corroborated in female osteoporotic subjects where we found decreased serum IL-

277 reas SERMS may be more effective when milder osteoporotic symptoms are present.

278 Intravertebral clefts occur frequently in osteoporotic VCFs of patients who present for vertebropl

279 9 [standard deviation]) with 422 symptomatic osteoporotic VCFs underwent 204 treatment sessions for o

280 and decreased analgesic use in patients with osteoporotic VCFs.

281 ease in severe, persistently mobile, clefted osteoporotic VCFs.

282 Osteoporotic vertebral and hip fractures are less freque

283 ed 131 patients who had one to three painful osteoporotic vertebral compression fractures to undergo

284 broplasty is commonly used to treat painful, osteoporotic vertebral compression fractures.

285 rentiation of donors with from those without osteoporotic vertebral fractures at 3.0 T than at 1.5 T.

286 otic control group (P<.001) or than elective osteoporotic women (P = .001) (medians, 5.58, 3.26, and

287 strozole-induced bone loss in osteopenic and osteoporotic women and might be offered in combination w

288 cy of clinical attachment loss in osteopenic/osteoporotic women in early menopause.

289 In postmenopausal osteoporotic women switching from teriparatide to denosu

290 ion study (DATA), in which 94 postmenopausal osteoporotic women were randomly assigned to receive 24

291 es in bone mineral density in postmenopausal osteoporotic women who transitioned between treatments.

292 ceiving risedronate (strata I and II) and in osteoporotic women who were all treated with risedronate

293 tion 2: ACP recommends that clinicians treat osteoporotic women with pharmacologic therapy for 5 year

294 ton absorptiometry (DPA) to demonstrate that osteoporotic women with vertebral fractures had lost sub

295 ity (estrogen-like effect) in postmenopausal osteoporotic women, but at the same time reduces the inc